Skip to main content

Table 2 Baseline characteristics of treated migraine attacks for patients using and not using migraine preventive medications

From: Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials

Characteristic (ITT population)Using preventive treatments N = 698Not using preventive treatments N = 3283
Baseline migraine severity
 Severe, n (%)174 (24.9)973 (29.6)
 Moderate, n (%)511 (73.2)2257 (68.7)
 Mild, n (%)13 (1.9)52 (1.6)
Time to dosing from onset of pain in hours, mean (SD)1.9 (4.3)1.9 (4.3)
Baseline symptoms
 Photophobia, n (%)537 (76.9)2522 (76.8)
 Phonophobia, n (%)439 (62.9)2048 (62.4)
 Nausea, n (%)316 (45.3)1416 (43.1)
 Vomiting, n (%)14 (2.0)80 (2.4%)
Baseline disability score
 Need complete bedrest, n (%)118 (16.9)585 (17.8)
 Marked interference, n (%)363 (52.0)1795 (54.7)
 Mild interference, n (%)209 (29.9)862 (26.3)
 Not at all, n (%)8 (1.1)41 (1.2)
  1. ITT intent-to-treat, N number of patients in subgroup of ITT population, n number of patients with stated characteristic, SD standard deviation
  2. p < 0.05 compared with not using preventives
\